

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A method of treating beta-thalassaemia comprising administering a medicament comprising a pharmaceutically effective amount of rapamycin or a structural analogue thereof to a patient in need of such treatment, wherein the beta-thalassaemia is therapeutically treated by induction of HbF.

2. (previously presented): The method of treating beta-thalassaemia according to claim 1, wherein the structural analogue is selected from the group comprising 7- (N-hydroxy)-acyl analogues, carbamoyl analogues and ureide analogues of rapamycin.

3. (currently amended): The method of treating beta-thalassaemia according to claim 1, wherein the rapamycin or the structural analogue is in combination with at least one ~~further~~ modifier of a transcription process selected from the group consisting of cytosine arabinoside, retinoic acid, plicamycin, mithramycin, hydroxyurea, guanine, guanosine, triphosphate (GTP), guanosine diphosphate (GDP) and guanosine monophosphate (GMP).

4. (currently amended): The method of treating beta-thalassaemia according to claim 2, wherein the rapamycin or the structural analogue is in combination with at least one ~~further~~ modifier of a transcription process selected from the group consisting of cytosine

arabinoside, retinoic acid, plicamycin, mithramycin, hydroxyurea, guanine, guanosine, triphosphate (GTP), guanosine diphosphate (GDP) and guanosine monophosphate (GMP).